Electrocore LLC

NASDAQ ECOR

Data sourced from iex and EODHD
Download Data

Electrocore LLC Research and Development (R&D) Expense Ratio 5 year CAGR for the quarter ending March 31, 2024: -61.30%

Electrocore LLC Research and Development (R&D) Expense Ratio 5 year CAGR is -61.30% for the quarter ending March 31, 2024, a -15.64% change year over year. The RD expense ratio measures the proportion of a company's research and development (R&D) expenses to its revenue. It is calculated by dividing the R&D expenses by the revenue. This ratio indicates the level of investment in R&D relative to the company's revenue generation. A higher ratio suggests a greater allocation of resources towards research and development activities, indicating a focus on innovation and potential future growth. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Electrocore LLC Research and Development (R&D) Expense Ratio for the quarter ending March 31, 2023 was 65.07%, a 32.30% change year over year.
  • Electrocore LLC Research and Development (R&D) Expense Ratio for the quarter ending March 31, 2022 was 49.18%, a 18.66% change year over year.
  • Electrocore LLC Research and Development (R&D) Expense Ratio for the quarter ending March 31, 2021 was 41.45%, a -80.03% change year over year.
  • Electrocore LLC Research and Development (R&D) Expense Ratio for the quarter ending March 31, 2020 was 207.56%, a -75.43% change year over year.
NASDAQ: ECOR

Electrocore LLC

CEO Mr. Daniel S. Goldberger
IPO Date June 22, 2018
Location United States
Headquarters 200 Forge Way, Rockaway, NJ, United States, 07866
Employees 68
Sector Healthcare
Industry Medical devices
Description

electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

StockViz Staff

September 19, 2024

Any question? Send us an email